• Publications
  • Influence

Claim Your Author Page
Ensure your research is discoverable on Semantic Scholar. Claiming your author page allows you to personalize the information displayed and manage your publications. Semantic Scholar automatically creates author pages based on data aggregated from public sources and our publisher partners.
  • Christian Hartmann Geisler, Arne Kolstad, +19 authors Erkki Elonen
  • Medicine
  • Blood
  • 2008 (First Publication: 1 October 2008)
  • Mantle cell lymphoma (MCL) is considered incurable. Intensive immunochemotherapy with stem cell support has not been tested in large, prospective series. In the 2nd Nordic MCL trial, we treated 160Expand
  • Christian Hartmann Geisler, Arne Kolstad, +18 authors Erkki Elonen
  • Medicine
  • British journal of haematology
  • 2012 (First Publication: 1 August 2012)
  • Mantle cell lymphoma (MCL) is a heterogenic non-Hodgkin lymphoma entity, with a median survival of about 5 years. In 2008 we reported the early - based on the median observation time of 4 years -Expand
  • Harald Holte, Sirpa Leppä, +16 authors Mikael Eriksson
  • Medicine
  • Annals of oncology : official journal of the…
  • 2013 (First Publication: 1 May 2013)
  • BACKGROUND Many patients with aggressive B-cell lymphomas and high clinical risk score still die of lymphoma after conventional R-CHOP chemoimmunotherapy. We hypothesized that intensifiedExpand
  • Niels Smedegaard Andersen, Lone Bredo Pedersen, +9 authors Christian Hartmann Geisler
  • Medicine
  • European journal of haematology
  • 2003 (First Publication: 1 August 2003)
  • OBJECTIVES The aim of the first Nordic mantle cell lymphoma (MCL) protocol was to study the clinical significance of an augmented CHOP induction chemotherapy followed by high-dose chemotherapy andExpand
  • Michael R Bishop, Robert M. Dean, +10 authors Dan Fowler
  • Medicine
  • Annals of oncology : official journal of the…
  • 2008 (First Publication: 1 November 2008)
  • BACKGROUND A graft-versus-lymphoma effect against diffuse large B-cell lymphoma (DLBCL) is inferred by sustained relapse-free survival after allogeneic stem-cell transplantation; however, there areExpand
  • M. Jerkeman, C. W. Eskelund, +11 authors A. Kolstad
  • Medicine
  • The Lancet. Haematology
  • 2018 (First Publication: 1 March 2018)
  • BACKGROUND Regimens based on ibrutinib alone and lenalidomide and rituximab in combination show high activity in patients with relapsed or refractory mantle cell lymphoma. We hypothesised that theExpand